Health Canada Adds Submission Class Data to Generic Review Tracker
Health Canada has enhanced its public drug review tracker with new submission class data, providing Canadians with more detailed information about generic medication applications under review, including the nine generic semaglutide submissions currently in the system.
Enhanced Transparency in Drug Reviews
As of March 20, 2026, Health Canada's Submissions Under Review (SUR) tracker now displays the submission 'class' for each application, including whether submissions were reviewed under specific regulatory pathways. This update applies to all completed submissions and provides additional context for patients and healthcare providers tracking the approval process.
The enhanced tracker affects all drug categories currently under review, including the highly anticipated Ozempic generic applications from nine different manufacturers.
Generic Semaglutide Applications Affected
The submission class data applies to the nine generic semaglutide applications currently under Health Canada review, which include submissions from:
- Sandoz Canada
- Apotex Inc.
- Teva Canada
- Taro Pharmaceuticals
- Dr. Reddy's Laboratories
- Sun Pharmaceutical
- Aspen Pharmacare
- Vimy Pharma
- Pharmather Holdings
Health Canada spokesperson Marie-Pier Burelle confirmed the agency remains "on track to meet review targets for generic semaglutide drug submissions" under the standard 180-day review timeline.
Improved Public Access to Information
The tracker enhancement represents Health Canada's commitment to transparency in the drug approval process. The submission class information helps distinguish between different types of applications, such as standard generic submissions, abbreviated new drug submissions, or applications requiring additional regulatory considerations.
Patients can now access more comprehensive information about generic applications for popular medications including Mounjaro and Wegovy alternatives through the public database.
Timeline for Generic Approvals
With semaglutide patents having expired on January 4, 2026, the enhanced tracker provides real-time visibility into the approval process for generic alternatives. Health Canada maintains its target of completing reviews within 180 days of submission, though complex applications may require additional time.
The generic semaglutide tracker on GLP1Prices.ca monitors these developments alongside the official Health Canada database, providing Canadians with consolidated information about expected approval timelines and pricing expectations.
Regulatory Context
The submission class data update coincides with increased public interest in generic medication approvals, particularly for high-cost prescription drugs. The enhanced transparency allows patients, healthcare providers, and insurance coverage checker systems to better understand the regulatory pathway for specific generic applications.
Health Canada's move to include submission class information follows similar transparency initiatives by other regulatory agencies worldwide, aimed at providing clearer communication about drug approval processes to stakeholders.
This article is for informational purposes only and does not constitute medical advice.
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
